Continuous nationwide surveillance of antibiotic resistance in invasive pneumococcal disease was performed in Germany between 1992 and 2000, with a total of 2586 strains being isolated. The average resistance rates to erythromycin and clindamycin were 7.7% and 3.5%, respectively, throughout the study period; 3.3% of strains were found to have intermediate resistance to penicillin. Over the study period an increase in both macrolide and penicillin resistance was observed. The percentage of strains exhibiting reduced susceptibility to penicillin increased from 1.8% in 1992 to 5.8% in 2000. A dramatic increase in resistance was observed with erythromycin, where the resistance rate rose from 3.0% in 1992 to 15.3% in 2000. Of the erythromycin-resistant strains, 86 (43.4%) and 111 (56.1%) belonged to the erm(B) and mef types of resistance, respectively. An analysis of macrolide consumption data during the study period showed that erythromycin resistance was highly correlated to the consumption of newer bd and od macrolides (r ‫؍‬ 0.89, P < 0.01).
Introduction
In the past decade macrolide resistance among clinical pneumococcal isolates has become a serious problem and resistance rates to these antibiotics have exceeded resistance rates to -lactams in some parts of the world. 1 Resistance to erythromycin in pneumococci was very low (Ͻ1%) in Germany in the 1980s. 2 A significant level of resistance (3.8%) was first observed among 131 pneumococcal strains isolated between 1988 and 1991. 3 Continuous surveillance of antibiotic resistance among pneumococcal strains isolated from invasive disease was launched in 1992, and the level of macrolide-resistant strains found among pneumococci (n ϭ 844) isolated between 1992 and 1994 was 3.8%. 4 In addition, a recent study on antibiotic resistance of pneumococci isolated mainly from respiratory tract specimens demonstrated resistance to clarithromycin in 10.6% of strains. 5 Two main mechanisms are known to account for pneumococcal macrolide resistance. The so-called MLS B phenotype of resistance confers co-resistance to most macrolides, lincosamides and streptogramin B antibiotics. Resistance is associated with the erm gene 6 and is due to methylation of a specific adenine residue resulting in reduced affinity between the MLS B antibiotics and the ribosome. The other type of resistance, the so-called M phenotype, results in resistance to the 14-and 15-membered macrolides and is caused by the presence of the mef(E) gene. 7 In addition, mutations in 23S rRNA and ribosomal protein L4 have been shown to account for resistance in pneumococci. 8 In this report we describe the emergence of macrolide and penicillin resistance among invasive pneumococcal strains isolated in Germany over the period 1992-2000.
Materials and methods
The German National Reference Center for Streptococci regularly receives all consecutive invasive pneumococcal isolates from 60 clinical microbiological laboratories throughout Germany. Each isolate is confirmed as Streptococcus pneumoniae by optochin susceptibility and bile solubility testing. MICs of penicillin, cefotaxime, tetracycline, erythromycin, vancomycin, teicoplanin, quinupristin-dalfopristin, ciprofloxacin and clindamycin are determined by the broth microdilution method using Mueller-Hinton broth (Difco Laboratories, Detroit, MI, USA) supplemented with 5% lysed horse blood (Oxoid, For the detection of erm(B) and mef(E) the primers described by Trieu-Cuot et al. 6 and by Tait-Kamradt et al. 10 were chosen. Preparation of DNA and the PCR were performed as described previously. 5 Pneumococcal strains were serotyped by Neufeld's Quellung reaction using type and factor sera provided by the Statens Serum Institut, Copenhagen, Denmark.
Antibiotic consumption data were kindly provided by the Institute for Medical Statistics (IMS), Frankfurt, Germany. These data are based on prescriptions issued by German hospitals and general practitioners. Data were provided as annual consumption units of the total German population for all macrolides (parenteral and oral drugs) for clindamycin and for the long-acting 'newer macrolides' azithromycin and clarithromycin. Data were analysed by calculating correlation coefficients (Pearson) between prescription data and resistance data according to Baquero. 11 The significance of the increase in resistance was determined by the Cochran-Armitage trend test. The influence of previous antibiotic treatment on resistance was analysed by Fisher's exact test. Subgroups of strains for serotyping were selected randomly.
Clinical data were collected by sending questionnaires covering patients' sex, age, clinical diagnosis, underlying disease and recent previous antibiotic therapy.
Results
A total of 2586 strains was isolated; of these, 2134 (82.5%) were recovered from blood, 314 (12.1%) from cerebrospinal fluid, 81 (3.1%) from pleural fluid and 57 (2.2%) from other normally sterile body sites.
The mean age of the study population was 57.9 years (range Ͻ1 month to 96 years). In adults aged Ͼ50, the rate of pneumococcal infection was approximately three-fold that of persons aged between 20 and 50 years; more than two-thirds (69.7%) of all reported infections occurred in the former age group. The male:female patient ratio was 1.2:1. Information on antibiotic therapy before the start of microbiological diagnosis was available for 1708 patients, showing that 23% of patients had been treated. Differences in antibiotic resistance among strains cultured from patients with or without previous antibiotic treatment were observed: resistance rates in the treated (n ϭ 1315; not previously treated, n ϭ 393) patients were as follows: penicillin, 3.3% (2.9%, not significant); erythromycin, 10.4% (6.6%, significant, P ϭ 0.02); tetracycline, 15.8% (11.9%, borderline significant, P ϭ 0.056).
Detailed data on underlying diseases were available in 717 cases. Cancer (11.3%), alcohol abuse (9.9%), diabetes mellitus (7.9%), plasmacytoma (7.8%) and leukaemia (7%) were the leading risk factors for pneumococcal disease. It is interesting to note that 5.4% of patients were HIV infected. In addition, 3.4% of patients had asplenia, and 6.5% underlying immunosuppression other than HIV or leukaemia.
The average rate of resistance to erythromycin and clindamycin was 7.7% and 3.5%, respectively, over the study period; 3.3% of strains were found to have penicillinintermediate resistance, but only two strains were fully resistant (MIC у 2 mg/L) ( Table 1) .
Over the study period a significant increase in both macrolide and penicillin resistance was observed. The rate of intermediate penicillin resistance rose significantly A total of 198 erythromycin-resistant strains were analysed for their underlying resistance determinants by PCR. Of these strains, 86 (43.4%) and 111 (56.1%) belonged to the erm(B) and mef(E) type of resistance, respectively. One strain showed no PCR product in repeated assays and needs further investigation.
Four hundred and fifty-eight pneumococcal isolates were selected randomly for serotyping. The predominant types were serotypes 14 (13.5%), 9V (7.6%) and 4 (6.8%) ( Table 2) . Overall, 88.2% of these invasive pneumococcal strains were represented in the 23-valent polysaccharide vaccine types.
Antibiotic resistance was associated with certain serotypes. Of the 198 erythromycin-resistant strains, 84 were selected randomly for serotyping. Of these, serotypes 14 (26.2%), 6B (21.4%), 23F (8.3%) and 9V (6.0%) were found to be predominant (Table 2) . Among the ermpositive strains, serotype 6B (34.1%) was predominant, whereas serotype 14 was predominant among the mef genotype, indicating the likelihood of clonal relatedness of those strains. Of 64 strains exhibiting reduced susceptibility to penicillin, 49 were serotyped, and resistance to this drug was found predominantly with serotypes 23F (22.4%), 9V (16.3%), 14 (10.2%), 6B (6.1%) and 4 (6.1%). Table 3 shows the patterns of co-resistance between different antibiotics. Of the erythromycin-resistant strains, 12.1% were also penicillin intermediate or resistant. However, 19.5% of the erm-positive strains exhibited reduced sensitivity to penicillin (Table 3) . Eighteen strains were resistant to penicillin (intermediate and resistant), erythromycin and tetracycline. Slight differences in macrolide and penicillin resistance between different geographical regions of Germany were observed (Table 4 ). In the present study 136 strains from children р16 years of age were randomly selected for serotyping (Table 2) . Serotypes 14 (13.2%), 6A (11.0%), 18C (8.8%), 9V (8.8%) and 19F (8.1%) were predominant.
Analysis of antibiotic consumption data showed that erythromycin resistance was highly correlated with the consumption of total macrolides (r ϭ 0.94, P Ͻ 0.01). When macrolides were divided into subgroups, erythromycin resistance appeared to be related mainly to newer macrolides (r ϭ 0.89, P Ͻ 0.01). Among those, the best correlation was seen with azithromycin (r ϭ 0.94, P Ͻ 0.01) and clindamycin (r ϭ 0.80, P Ͻ 0.01), whereas only a moderate correlation was seen with roxithromycin (r ϭ 0.49, P Ͻ 0.01). The consumption of erythromycin was not correlated with erythromycin resistance (r ϭ -0.86). Clindamycin consumption is also correlated with erythromycin resistance in S. pneumoniae in Germany (r ϭ 0.97, P Ͻ 0.01) (Figure 2 ).
Discussion
In the present study of 2586 pneumococcal strains isolated from patients with invasive pneumococcal disease, only 3.3% of strains were found to have intermediate resistance to penicillin. Highly penicillin-resistant strains were only rarely observed (n ϭ 2), underscoring the relatively favourable level of -lactam resistance of S. pneumoniae in Germany. The resistance rate to penicillin G found in invasive disease is slightly lower and thus comparable to that reported in pneumococcal respiratory tract infection in both children and adults. 5, 12 The relatively favourable level of -lactam resistance in Germany has also been documented by other investigators. Marre & Trautmann 13 reported that Ͼ95% of 105 pneumococcal strains isolated in Germany between 1994 and 1995 were susceptible to penicillin. In a study performed on pneumococcal isolates from eastern Germany, 100% of 105 pneumococci were susceptible to penicillin.
14 In addition, a worldwide study of respiratory tract infections (the Alexander Project) demonstrated a penicillin resistance rate of about 7.2% (intermediate resistance) among strains isolated in one single institution in southern Germany in 1998. 1 A multicentre, collaborative study performed in Asia and Europe during the winter of 1997-1998 on the in vitro activity of selected antimicrobial agents against common respiratory pathogens reported 92% of pneumococcal isolates in Germany to be susceptible to penicillin, whereas only 34% were still susceptible to penicillin G in France and Spain. 15 The dramatic increase in macrolide resistance among invasive pneumococcal strains is one of the most important findings of the present study. As in many other countries, macrolide resistance has surpassed the level of -lactam resistance in Germany. 16 In contrast to invasive disease, the level of macrolide resistance is lower in respiratory tract infections in Germany. 5 It is interesting to note that a high rate of macrolideresistant strains (13.8%), including strains isolated in 1997-1998, was also documented in a population-based study of children. 17 In the study on respiratory tract infections by Reinert et al., 5 one notable finding was that macrolide resistance rates (range 1.5-21.3%) can show pronounced variations between geographical regions within Germany, a finding that could not be documented by the present study on invasive disease.
The relevance of antibiotic resistance to the outcome of disease has been widely discussed for -lactams.
18,19 At present, data on the influence of low-level macrolide resistance on outcome are controversial. A retrospective study from the USA of 41 patients admitted with bacteraemia caused by low-level macrolide-resistant pneumococci demonstrated that four patients had previously taken either azithromycin or clarithromycin for 3-5 days. 20 These authors state that even low-level resistance to macrolides can lead to clinical failure, and resistance to macrolides should be considered during the selection of empirical therapy for patients with presumed pneumococcal infections.
In Germany macrolide resistance in invasive disease is caused by the high prevalence of both resistance phenotypes (MLS B phenotypes, 43.4% of macrolide-resistant strains; M phenotype, 56.1% of macrolide-resistant strains), whereas in pneumococcal isolates from respiratory tract infections only 20.5% of macrolide-resistant strains show a macrolide efflux mechanism. 5 Cross-resistance between -lactams, tetracycline and macrolides, especially in MLS B strains, is widespread in Germany; 12.1% of all macrolide-resistant isolates were also found to be penicillin non-susceptible. Penicillinintermediate strains showed co-resistance to macrolides in 28.6% of isolates, limiting the use of this class of antibiotics in the treatment of infections caused by penicillin nonsusceptible strains.
The prevalence of these resistance genotypes is subject to major variations between countries. In Italy, macrolideresistant pneumococci were isolated at a rate increasing from 6% in 1993 to 31.7% in 1998. In a collection of 161 erythromycin-resistant S. pneumoniae, c. 90% of isolates possessed a constitutive MLS B mechanism of resistance.
21
In a recent Belgian study of 100 S. pneumoniae isolates, 33 were erythromycin resistant. Of the 33 erythromycinresistant S. pneumoniae isolates, 9.1% showed the M resistance phenotype.
22
In one strain from the current study the resistance determinant could not be identified. This strain needs further investigation and may possess a hitherto unknown resistance determinant or may have mutations in 23S rRNA and ribosomal protein L4, which have recently been shown to account for resistance in pneumococcal strains selected in vitro by macrolide passage. 8 In addition, resistance may also be due to the presence of the erm(A) gene, as recently reported from Greece. 23 Antibiotic consumption has been identified as contributing to the emergence of resistance in Streptococcus pyogenes and S. pneumoniae. 24, 25 As in other countries, increased usage of macrolides to be taken once or twice daily is recorded in Germany, whereas the erythromycin consumption level seems to be stable ( Figure 2) . As in Spain, a progressive increase in the erythromycin resistance curve was seen after the consecutive introduction of bd and od macrolides, which contributed to the increase in total macrolide consumption, superseding tds macrolide prescription. 24 Although this analysis cannot establish an unequivocal causal relationship between antibiotic consumption and pneumococcal resistance, the data are highly consistent with the hypothesis that widespread use of macrolides, mainly of bd and od macrolides, is a primary contributory factor in the emergence of resistance. 11, 24, 25 As antibiotic resistance is a major problem worldwide, 4 In summary, this study documents an emergence of macrolide resistance among invasive pneumococci in Germany, possibly driven by uncritical usage of macrolides. Nevertheless, the level of resistance in Germany is lower than those reported from southern and south-eastern Europe. Macrolide resistance in particular may now represent a serious problem for treatment of pneumococcal infection in Germany. Therefore, the resistance profile of pneumococci should be carefully monitored in the future, and broad usage of macrolides should be reconsidered. 
